S-1: Azitra Inc. Files for Potential $22.6 Million Stock and Warrant Offering

Azitra Inc. has filed a registration statement for the potential resale of up to 66,889,632 shares of common stock and 6,688,963 shares underlying warrants by Alumni Capital LP, aiming to raise up to $22.6 million for working capital and general corporate purposes.

Summary

• Azitra Inc., a clinical biopharmaceutical company, has filed a registration statement for a potential offering involving its common stock and warrants.
• The offering includes up to 66,889,632 shares of common stock and up to 6,688,963 shares of common stock underlying warrants, which may be resold by Alumni Capital LP.
• The shares and warrants have been or may be issued and sold to Alumni Capital pursuant to a purchase agreement dated April 24, 2025.
• Azitra may receive up to $20 million from the sale of shares to Alumni Capital and up to $2.6 million upon exercise of the warrants for cash, totaling a potential $22.6 million.
• The company intends to use any proceeds from the sale of shares and exercise of warrants for working capital and other general corporate purposes.
• Alumni Capital will determine the prices at which it may resell the shares and warrant shares based on the prevailing market price or in negotiated transactions.
• The company's common stock is listed on the NYSE American under the symbol AZTR, and the last reported sale price on April 25, 2025, was $0.32 per share.
• The purchase price of the shares that the Company elects to sell to the Purchaser pursuant to the Purchase Agreement will be equal to the lowest daily volume weighted average price of the Common Stock during the period commencing on the date that the Company delivers a notice requiring the purchase of Shares by the Purchaser and ending on the earlier to occur of (i) five business days immediately following such date and (ii) the date on which the Purchaser notifies the Company that it is prepared to proceed with the relevant closing, multiplied by 90%.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the potential capital raise is positive, the document also highlights risks and uncertainties, including the company's ability to continue as a going concern and potential stock dilution.

Positives

• The potential capital injection of up to $22.6 million could provide Azitra with additional resources for its operations and clinical trials.
• The company retains control over the timing and amount of shares sold to Alumni Capital under the purchase agreement.
• The company has the right to terminate the Purchase Agreement at any time, at no cost or penalty, upon written notice to Alumni Capital except after submitting a purchase notice and before delivering the related Warrant that is due and owed to Alumni Capital.

Negatives

• The company will not receive any proceeds from the resale of shares of Common Stock by Alumni Capital.
• The market price of the Common Stock may be subject to fluctuation and volatility.
• The issuance of Common Stock to the Selling Stockholder may cause substantial dilution to our existing stockholders, and the sale of such shares acquired by the Selling Stockholder could cause the price of our Common Stock to decline.

Risks

• Investing in the company's securities involves a high degree of risk, and investors may lose all or part of their investment.
• The company will need additional financing to execute its business plan, and such financing may not be available on reasonable terms or at all.
• The report of the company's independent registered public accounting firm states that there is substantial doubt about its ability to continue as a going concern.
• The market price of the company's common stock may be subject to fluctuation and volatility.
• Future capital raises may dilute your ownership and/or have other adverse effects on our operations.

Future Outlook

Azitra intends to advance its lead programs, ATR-12 and ATR-04, through clinical trials and broaden its platform by selectively exploring strategic partnerships. The company expects to report initial safety results of the first patients dosed in its ATR-12 Phase 1b clinical trial in Netherton syndrome patients in early 2025 with full results anticipated in the second half of 2025. The company expects to dose the first patient in the ATR-04 Phase 1/2 clinical trial in the first half of 2025.

Management Comments

• Our goal is to leverage our platforms and internal microbial library bacterial strains to create new therapeutics that are either engineered living organisms or engineered proteins or peptides to treat skin diseases.
• We believe that we have established a unique position in advancing the development of biologics for precision dermatology.

Industry Context

The dermatology drug market is experiencing considerable growth and is expected to continue to grow. According to Vision Research Reports, the dermatology drug market surpassed $17 billion in 2021 and is expected to grow at a compound annual growth rate of 8.8% through 2030.

Stakeholder Impact

• Shareholders may experience dilution if the company issues a significant number of shares to Alumni Capital.
• The potential capital raise could provide the company with additional resources to advance its clinical programs, potentially benefiting patients.
• Employees may benefit from the company's continued operations and growth if the capital raise is successful.

Next Steps

• The company will continue to advance its lead programs, ATR-12 and ATR-04, through clinical trials.
• The company will selectively explore strategic partnerships to broaden its platform.
• The company will use the proceeds from the potential offering for working capital and general corporate purposes.
• The company expects to report initial safety results of the first patients dosed in its ATR-12 Phase 1b clinical trial in Netherton syndrome patients in early 2025 with full results anticipated in the second half of 2025.
• The company expects to dose the first patient in the ATR-04 Phase 1/2 clinical trial in the first half of 2025.

Key Dates

Keywords

common stock, warrants, offering, Alumni Capital, Azitra, shares, purchase agreement, biopharmaceutical, precision dermatology, financing